U.S. Alzheimers Disease Diagnostics Market Estimations (2025 - 2035)
The U.S. Alzheimers disease diagnostics market covers tests and imaging used to detect and confirm Alzheimer's disease in the United States, including amyloid and tau PET, MRI and other brain imaging, cerebrospinal fluid biomarker assays, blood-based pTau and amyloid biomarker tests and digital cognitive assessments, used by hospitals and imaging centres, reference and hospital laboratories and neurology and primary care clinics.
📄Report ID:2500
|
📊Format: Databook
|
📅Published: 17 November 2026
|
⚡Delivery: Immediate